Novo, Lilly shares fall as Trump touts ‘much lower’ Ozempic price

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00
Total annual spending on GLP-1 drugs increased by more than 500% in five years, from $13.7 billion in 2018 to $71.7 billion in 2023. (Adobe stock image)

Novo Nordisk A/S and Eli Lilly and Co. shares fell after President Donald Trump said the price of the blockbuster diabetes drug Ozempic could come down to just $150 a month.

The U.S. list price of Ozempic, which Trump called “the fat loss drug,” is roughly $1,000 for a month’s supply. Trump told reporters on Thursday that the cost of the drug, made by Novo, will soon be “much lower.” Lilly sells similar treatments, including Mounjaro, for Type 2 diabetes, and the blockbuster weight-loss dug Zepbound.

“Those are going to be $150 out of pocket,” he said during a press conference in the Oval Office.

Novo’s shares fell as much as 7% in Copenhagen trading on Friday, the most since July. The drugmaker has dropped about 58% in the last 12 months amid concerns over its ability to compete in the weight-loss market.

Shares of Lilly had fallen by just over 3% by midday Friday.

Trump’s comments came during an event focused on a deal his administration struck with Germany’s Merck KGaA to cut prices for fertility treatments in exchange for a reprieve on looming pharmaceutical tariffs. Pacts have also been announced with Pfizer Inc. and AstraZeneca Plc, and investors have been anticipating similar action with the makers of the blockbuster weight-loss medicines.

Dr. Mehmet Oz, head of the Centers for Medicare and Medicaid Services, was quick to clarify that talks over the price of weight-loss drugs are still ongoing.

“We haven’t negotiated those yet,” he said.

Still, the comments “signal aggressive posturing” in the negotiations, Evan Seigerman, an analyst for BMO Capital Markets, wrote in a note. However, the negotiated price may not present a true fundamental change to Novo’s business, he said. That’s because people with insurance already pay as little as $25 a month, and the true net price of Ozempic after rebates for insurers is probably about 60% to 70% less than the published list price.

Novo has been in talks about lowering the cost of its medicines since Trump sent letters to 17 of the largest pharmaceutical companies demanding they cut prices. Ozempic and its sister drug Wegovy were also selected for price negotiations under the Inflation Reduction Act, or IRA.

“We’re going to be rolling those out over time,” Oz said. “The GLP-1 category of drugs, which includes Ozempic, have not been negotiated yet.”

When asked about a timeline for the negotiations, Trump said prices would come down “pretty fast.”

Oz once again jumped in to say that negotiations with the companies were ongoing and won’t be closed until the president is happy with the results.

Medicare, the U.S. health program for seniors, was already in the IRA talks on lower prices for Ozempic and Wegovy under a plan pushed through by former President Joe Biden to reduce drug costs. The deadline for those negotiations is Nov. 1, with the lower prices taking effect in 2027.

Indianapolis-based Eli Lilly and Co. launched its direct-to-consumer business, LillyDirect, in 2024. In February, Lilly cut prices for patients paying for single-dose Zepbound vials without insurance by $50 a month for 2.5 milligrams, a common starting dosage, and 5 milligrams. The charge dropped $349 or $499 a month, respectively. (Mounjaro is not available on LillyDirect.)

With its Zepbound Self Pay Journey Program, the company also introduced higher dosages of Zepbound, 7.5 or 10 milligram vials, for $499 on first fill and refills if done within 45 days of the medicine’s previous delivery. If patients refill prescriptions outside of the 45-day window, the cost is $599 a month and $699 a month, respectively.

Please enable JavaScript to view this content.

Story Continues Below

2 Comments

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In